Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

NCT06225843 is registered in ClinicalTrials.gov with Alethia Biotherapeutics as lead sponsor.

NCT NCT06225843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06225843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis
Lead sponsor
Alethia Biotherapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
February 15, 2024
Completion date
June 30, 2026
Enrollment
17 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer